Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 4, 2009, Pages 595-600

  Sender, Vicky ^a   Hofmeister Mielke, Nicole ^a   Sievert, Kathrin ^b   Teifke, Jens Peter ^c   Vogel, Heike ^b   Baumgart, Joachim ^d   Pichlmeier, Uwe ^d   Freund, Mathias ^a   Casper, Jochen ^a   Wolff, Daniel ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^d MEDAC GMBH   (Germany)

Author keywords

BMT; GVHD; Total body irradiation; Treosulfan

Indexed keywords

TREOSULFAN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ARTICLE; AUTOPSY; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; BUSULFAN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; GRAFT SURVIVAL; RATS; RATS, INBRED BN; RATS, INBRED LEW; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 70449099707     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970902865683     Document Type: Article

References (32)

1. Davis, W., Ross, W. C. The formation of epoxides from cytotoxic polyol methanesulphonates under physiological conditions. Biochem Pharmacol. 1963,12,915-917
2. Feith, P.W. Studies on Epoxide formation from (2S,3S)-Threitol 1,4-Bismethanesulfonate. The preparation and biological activity of (2S, 3S) - 1,2-epoxy-3,4-butanediol 4-methanesulfonate. J Med Chem. 1970,13(6), 1173-1175
3. Hilger, R.A., Harstrick, A., Eberhardt W., Oberhoff C., Skorzec M., Baumgart J., et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol. 1998,42(2),99-104. (Pubitemid 28267289)
4. Hartley, J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer. 1999,79(2),264-266
5. Fennelly, J. Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma. Br JObstet Gynaecol. 1977,84(4),300-303
6. Duncan, I.D., Clayton, L.A. Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan-a phase II study. Br J Obstet Gynaecol. 1985,92(7),762-767
7. Masding, J., Sarkar, T.K., White, W.F., Barley, V.L., Chawla, S.L., Boesen, E. et al. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol. 1990,97(4),342-351
8. Gropp, M, Meier, W., Hepp, H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol. 1998,71(1),94-98
9. Breitbach, G.P., Meden, H., Schmid, H., Kuhn, W., Sass, G., Schach, S. et al. Treosulfan in the treatment of advanced ovarian cancer: A randomised co-operative multicentre phase III-study. Anticancer Res. 2002,22(5),2923-2932
10. Köpf-Maier, P., Sass, G. Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother Pharmacol. 1992,31(2),103-110
11. Köpf-Maier, P., Sass, G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol. 1996,37(3),211-221
12. Köpf-Maier, P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. In Vivo (Athens, Greece). 1998,12(3),275-288
13. Neale, M.H., Myatt, N., Cree, I.A., Kurbacher, C.M.,Foss, A.J., Hungerford, J.L. et al. Combination chemotherapy for choroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999,79(9-10),1487-1493
14. Neuber, K., tom Dieck, A., Blodorn-Schlicht, N., Itschert, G., Karnbach, C. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res. 1999,9(2),125-132
15. Harstrick, A.W., Wilke, H., Eberhardt W. et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie. 1996,19,153-156
16. Sjöö, F., Hassan, Z., Abedi-Valugerdi, M., Griskevicius, L., Nilsson, C., Remberger, M. et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exper Hematol. 2006,34(1),115-121
17. Weissert, R., Wiendl, H., Pfrommer, H., Storch, M.K., Schreiner B., Barth, S., et al. Action of treosulfan in myelinoligodendrocyte- glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. Journal of Neuroimmunology. 2003,144(1-2),28-37.
18. Scheulen, M.E., Hilger, R.A., Oberhoff, C., Casper, J., Freund, M., Josten, K.M. et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 2000,6(11),4209-4216
19. Casper, J., Knauf, W., Kiefer, T., Wolff, D., Steiner, B., Hammer, U., et al. Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004,103(2),725-731
20. Beelen, D.W., Trenschel, R., Casper, J., Freund, M., Hilger, R.A., Scheulen, M.E. et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005,35(3),233-241
21. Koenigsmann, M., Mohren, M., Jentsch-Ullrich, K., Franke, A., Becker, E., Heim, M., et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant. 2004,34(6),477-483
22. Sauer, M., Zeidler, C., Meissner, B., Rehe, K., Hanke, A., Welte, K., et al. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2007,39(3),143-147
23. Greystoke, B.S., Carr, T.F. et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol. 2008, 142(2),257-262
24. Fichtner, I., Becker, M., Baumgart, J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer. 2003,39(6),801-807
25. Meinhardt, G., Dayyani, F., Jahrsdorfer, B., Baumgart, J., Emmerich, B., Schmidmaier, R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol. 2003,122(6),892-899
26. Schmidmaier, R., Oellerich, M., Baumgart, J., Emmerich, B., Meinhardt, G. Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. ExperHematol. 2004,32(1),76-86.
27. Munkelt, D., Koehl, U., Kloess, S., Zimmermann, S.Y., Kalaaeoul, R., Wehner, S., Schwabe, D., Lehrnbecher, T., Schubert, R., Kreuter, J., Klingebiel, T., Essner, R. cytotoxic effects of treosulfan and busulfan against leukaemic cells of pediatric patients. Cancer Chemother Pharmacol. 2008,62,821-830
28. Shimoni, A., Hardan, I., Shem-Tov, N. Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma. 2007,48(12),2352-2359
29. Westerhof, G.R., Ploemacher, A. B., Blokland, I., Dillingh, J.H., McGown, A.T., Hadfield MJD, Down, J.D. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients1. Cancer Res. 2000,60,5470-5478
30. Ploemacher, R.E., Johnson, K.W., Rombouts, E.J., Etienne, K., Westerhof, G.R., Baumgart J., et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant. 2004,10(4),236-245
31. Reichle, A., Berand A., Andreesen R. Treosulfan-Based tandem high-dose chemo-immuno-therapy with autologous stem cell transplantation for relapsed and refractory aggressive bcelllymphomas. Blood. 2005,106(11).
32. Wandt, H., Schaefer-Eckart, K., Wilhelm, M. Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica. 2005,90(9),1292-1294